Drug Trial Radar · NCT06094777
A Study of HY-0102 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Dec 18, 2023
Primary completion
Jun 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of HY-0102 and obtain the preliminary efficacy information of patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
HY-0102Drug
Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of drug limited toxicities (DLTs)Time frame: From Time of First dose through DLT observation period, 28 days
- Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs)Time frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
- Number of patients with changes in laboratory parameters from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
- Number of patients with changes in electrocariogram (ECG) from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
- Number of participants with changes in clinically significant vital sign from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.